Priapism

Summary

Priapism (MONDO:0004745) is a disease and 8 clinical trials. Top therapeutic interventions include crizanlizumab and alanine. A subtype of peripheral vascular disease — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Prevalence: 1-9 / 100 000 (Europe) [Orphanet-validated]
• Clinical trials: 8

Clinical features

Epidemiology

Prevalence records

1 prevalence record(s), Orphanet:

Type	Class	Value	Geography	Validation
Point prevalence	1-9 / 100 000		Europe	Validated

Identifiers

Disease identifiers

Field	Value
Canonical name	priapism
Mondo ID	MONDO:0004745
MeSH	D011317
Orphanet	140949
DOID	DOID:9286
ICD-10-CM	N48.3
ICD-11	1983776037
SNOMED CT	6273006
UMLS	C0033117
MedGen	19462
GARD	0019933
Is cancer (heuristic)	no

Also known as: low-flow priapism · mentulagra

Disease family

This is a subtype of peripheral vascular disease. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › cardiovascular disorder › vascular disorder › peripheral vascular disease › priapism

Related subtypes (10): diabetic peripheral angiopathy, telangiectasis, intermittent vascular claudication, peripheral arterial disease, mesenteric vascular occlusion, Raynaud disease, thromboangiitis obliterans, erythromelalgia, May-Thurner syndrome, livedo reticularis

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

No approved or late-stage (phase ≥3) drug is indicated for this disease; the following are in earlier-phase trials only.

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Crizanlizumab, Sildenafil, Tadalafil.

Clinical trials & evidence

Clinical trials

Clinical trials: 8.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	4
PHASE2	3
EARLY_PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00538564	PHASE2	WITHDRAWN	Tadalafil for Treatment of Priapism in Men With Sickle Cell Anemia
NCT00940901	PHASE2	COMPLETED	Sildenafil for Treatment of Priapism in Men With Sickle Cell Anemia
NCT03938454	PHASE2	COMPLETED	A Study to Evaluate the Safety and Efficacy of Crizanlizumab in Sickle Cell Disease Related Priapism
NCT01940718	EARLY_PHASE1	WITHDRAWN	Androgen Regulation of Priapism in Sickle Cell Disease
NCT04932902	Not specified	ENROLLING_BY_INVITATION	ManAgement of pRiapiSm and Its Impact on Outcomes
NCT00300235	Not specified	COMPLETED	Priapism in Boys and Men With Sickle Cell Disease - Demographics, Characteristics and Prevalence
NCT06098755	Not specified	WITHDRAWN	The Sequestration of Holistic Stress Management Techniques for Adults
NCT07391709	Not specified	COMPLETED	Investigation of the Protective Effect of Alpha Lipoic Acid on Ischemic Reperfusion Damage in Ischemic Priapism in Rats

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
CRIZANLIZUMAB	4	1
ALANINE	3	1
CHEMBL139521	0	1